Breaking Finance News

TG Therapeutics TGTX (NYSE:TGTX) stock price target increased to $33.00, issued a report today by H.C. Wainwright

Having a price of $8.63, TG Therapeutics TGTX (NYSE:TGTX) traded -2.33% lower on the day. With the last close down -25.13% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the same period. TG Therapeutics TGTX has recorded a 50-day average of $11.29 and a two hundred day average of $11.22. Volume of trade was up over the average, with 2,173,759 shares of TGTX changing hands over the typical 1,225,080

In a report released on 11/14/2017 H.C. Wainwright increased the target of TG Therapeutics TGTX (NYSE:TGTX) to $33.00 stating a potential upside of 2.82%.

See Chart Below

TG Therapeutics TGTX (NYSE:TGTX)

TG Therapeutics TGTX has a 52 week low of $4.10 and a 52 week high of $15.35 The company’s market cap is currently $0.

About TG Therapeutics TGTX (NYSE:TGTX)

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.